Form 4: Natera Executive Sells Shares Under 10b5-1 Plan

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock for approximately $596,000 under a pre-arranged 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President, Clinical Diagnostics of Natera, Inc. (NTRA), reported the sale of 3,000 shares of common stock.
• The transactions occurred on November 3, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• The shares were sold at weighted average prices of $198.026, $199.1023, and $199.74.
• Following these transactions, Moshkevich beneficially owns 112,061 shares of Natera common stock directly.

Sentiment

Score: 5

Explanation: The sale of shares by an insider is generally viewed neutrally to slightly negatively. However, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, negative material non-public information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to immediate company news.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan provides transparency and suggests a pre-planned financial move rather than a reaction to company performance.

Key Dates

Recommendation

The reported transaction is an insider sale executed under a Rule 10b5-1 trading plan, which indicates a pre-scheduled divestment rather than a reaction to recent company performance or outlook. While insider selling can sometimes be a negative signal, the pre-planned nature reduces its immediate interpretative impact on the company's fundamentals. Without additional information on Natera's financial performance or strategic direction, this single Form 4 filing does not provide sufficient grounds for a strong buy or sell recommendation, thus a 'hold' stance is appropriate.

Keywords

Natera, NTRA, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Solomon Moshkevich, Clinical Diagnostics